Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Diphenylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.86 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.86 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.86 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.86 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.55 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.52 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.86 |
| ▸ | TSHR | P16473 | 5/20 | 0.86 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.86 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | AR | P10275 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenylamine SCHEMBL11684039 | 1.00 | HSD17B10 (0.92) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL28099388 | 0.96 | HSD17B10 (0.86) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL27577956 | 0.96 | HSD17B10 (0.86) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL11632853 | 0.96 | HSD17B10 (0.86) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL6470076 | 0.96 | HSD17B10 (0.86) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL11650896 | 0.96 | HSD17B10 (0.86) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL1619083 | 0.96 | HSD17B10 (1.00) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL301493 | 0.96 | HSD17B10 (1.00) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL229 | 0.96 | HSD17B10 (1.00) | HSD17B10ALDH1A1TDP1TSHRALOX12 | |
| Diphenylamine SCHEMBL3003404 | 0.96 | HSD17B10 (1.00) | HSD17B10ALDH1A1TDP1TSHRALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| WO-2025085311-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF KMT2D-DEFICIENT CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-24 | — | — | WO | claimed |
| CN-119707943-A | Organic fluorescent dye and preparation method and application thereof | 长三角物理研究中心有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119462474-A | Preparation method and application of parathyroid gland targeting cyanine dye photosensitizer | 大连理工大学 | 2025-02-18 | — | — | CN | claimed |
| CN-118908958-A | CDK4/6 small molecule fluorescent probe and preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2024-11-08 | — | — | CN | claimed |
| CN-118883757-A | Analysis method of related substances of Schiff base compounds | 南京正大天晴制药有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-116082109-B | Synthesis method of stable isotope labeled diphenylamine-2, 2', 4', 6' -D6 | 上海安谱实验科技股份有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-118439989-A | Preparation method of high-purity indocyanine green | 武汉百科药物开发有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-116715976-B | Chiral carbon-containing pentamethine cyanine dye, and preparation method and application thereof | 大连理工大学 | 2024-08-06 | — | — | CN | claimed |
| CN-118221562-A | DIR' preparation method | 湖北英纳氏生物科技有限公司 | 2024-06-21 | — | — | CN | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-5147621-A | Amine stabilizer | CHEMIE AG BITTERFELD-WOLFEN (DE) | 1992-09-15 | — | — | US | claimed |
| US-4739121-A | Process for otho- and para-alkylating diphenylamines | THE B. F. GOODRICH COMPANY (US) | 1988-04-19 | — | — | US | claimed |
| US-4708873-A | BIPHENAMINE AND ALOE VERA | SCHULTE THOMAS L (US) | 1987-11-24 | — | — | US | claimed |
| US-4626530-A | Treatment of eye inflammation with biphenamine | SCHULTE THOMAS L (US) | 1986-12-02 | — | — | US | claimed |
| US-4497824-A | Method of chemically debriding ulcerated necrotic tissue | SCHULTE THOMAS L | 1985-02-05 | — | — | US | claimed |
| US-4369190-A | Analgesic composition and use thereof to ameliorate intractable pain | SCHULTE THOMAS L | 1983-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | PTGS1 1078/4885SLC6A2 4479/4885PTGS2 1745/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | PTGS1 1195/4885SLC6A2 278/4885PTGS2 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.